446286-90-4 Usage
General Description
2-Bromo-5-(piperazin-1-yl)pyrazine is a chemical compound with the molecular formula C8H11BrN4. It is a pyrazine derivative, which is a six-membered aromatic ring containing two nitrogen atoms at positions 1 and 4 and a bromine atom at position 2. The compound also contains a piperazine ring, which is a six-membered heterocyclic ring containing two nitrogen atoms. 2-Bromo-5-(piperazin-1-yl)pyrazine is used in the synthesis of various pharmaceuticals and agrochemicals. It exhibits potential pharmacological activity and is researched for its applications in treating various medical conditions. Additionally, it is also used as a building block in organic synthesis for the preparation of new chemical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 446286-90-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,6,2,8 and 6 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 446286-90:
(8*4)+(7*4)+(6*6)+(5*2)+(4*8)+(3*6)+(2*9)+(1*0)=174
174 % 10 = 4
So 446286-90-4 is a valid CAS Registry Number.
InChI:InChI=1/C8H11BrN4/c9-7-5-12-8(6-11-7)13-3-1-10-2-4-13/h5-6,10H,1-4H2
446286-90-4Relevant articles and documents
INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
-
Page/Page column 253, (2017/11/10)
Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
-
Page 296, (2010/02/10)
This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
